The COMPPARE Coordinating Center announced that the study achieved 75% enrollment on May 3, 2022.
COMPPARE realized both a remarkable overall accrual rate and an exceptional accrual rate of minorities, despite the ongoing challenges presented by COVID-19. In fact, the study stands to become a model for patient-centric clinical research in the future: As of April 1, 2022, enrollment of African American men was 15.4% (333/2156), exceeding the rate of 14.8% (275/1855) last fall and the original goal of 10%.
The study, funded by the Patient-Centered Outcomes Research Institute (PCORI), will compare the quality of life, side effects, and cure rates for prostate cancer patients treated with proton therapy or photon therapy. COMPPARE emphasizes patient-centered outcomes and will help future patients make informed treatment decisions. The results will also provide insurers with the data needed to make coverage and policy decisions around the use of proton therapy for prostate cancer.
As of May 20, 2022, COMPPARE had enrolled 591 randomized control trial (RCT) proton participants, 900 pragmatic proton participants, and 791 photon participants, for a total of 2,282 patients. The pragmatic proton arm has closed, achieving 100% of its goal, and the RCT proton arm is currently only nine patients away from its 600-patient goal.
“The dedication of our administrative team, partner sites, Patient Stakeholder and Minority Engagement Groups, and our enrollees has made this milestone achievement possible,” said Nancy Mendenhall, MD, COMPPARE Principal Investigator. “We will continue to work together to make a difference in the lives of all those facing a prostate cancer diagnosis.”